Business Environment

In alignment with Prognomix mission and key assets, we have defined our current business environment as the application of Personalized Medicine to diabetic patient treatment, prevention and assistance in development of novel therapies.

Personalized Medicine

Personalized Medicine can be defined as the use of genomic and molecular data to better target the delivery of health care, facilitate the discovery and clinical testing of new products, and help determine a person's predisposition to a particular disease or condition”.

According the Personalized Medicine Coalition, of which Prognomix is an active member (May 2009), the promise of personalized medicine for which tangible evidence already exists, includes the ability to:

  • Shift emphasis in medicine from reaction to prevention
  • Enable the selection of optimal therapy
  • Make the use of drugs safer by avoiding or limiting adverse drug reactions
  • Reduce the time and cost of clinical trials
  • Revive drugs that are failing in clinical trials or were withdrawn from the market
  • Reduce the overall cost of healthcare

Personalized Medicine has the potential to significantly change the landscape of the healthcare system, as well as the pharmaceutical industry paradigm. Following recent advancement in various fields, and mainly information technologies and genomics, Personalized Medicine started to see its first regulatory approvals and tangible applications. This is most evident for companion diagnostic applications based on patient’s genomic information. As of today, a limited number of drugs on the market are already “required” by the FDA, in the label information, to be used in conjunction with a companion diagnostics, and in the next 10 years, an estimated 10 to 20% of drugs in development will be associated to genetic testing.

The market of Molecular Companion Diagnostics is expected to grow by a magnitude of ten during 2010-2016 period. Most of the successful applications of Personalized Medicine is up to now confined to the sphere of monogenic disorders. In polygenic, complex diseases the success is limited to oncology, where the therapeutic profile recommendations are increasingly guided by tumor’s genetic makeup. In most of complex diseases of polygenic character, modified in penetrance by interaction with environment, the yield of information from individual genome is only forthcoming. Prognomix is fully dedicated to this endeavour.

Additional information on Personalized Medicine can be found on the PMC website.


Type 2 diabetes is a very common condition with a continuous growing prevalence rate both in developed and developing countries. Recent estimates suggest that 285 million people throughout the world have diabetes, mainly type 2 diabetes (T2D). This number was 194 million in 2003 and is expected to increase to 330, maybe even 438 million, by 2030. People with T2D are at substantially increased risk of developing complications (about 20% cardiovascular complications over a 5-year period), both macrovascular (coronary heart disease and stroke) and microvascular (retinopathy and nephropathy).

The economic burden of diabetes and its complication is a growing concern. As an example, healthcare cost resulting from complications of T2D diabetes was $58 billion in the US in 2007.

Additional information on diabetes and its complications can be found on the International Diabetes Federation website.